АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПРИ ВПЕРВЫЕ ВЫЯВЛЕННОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
Аннотация
Статья посвящена вопросу современной тактики назначения антитромботических препаратов у лиц с впервые выявленной фибрилляцией предсердий – одним из вариантов наиболее распространенного нарушения ритма, связанного с высоким риском развития тромбоэмболических осложнений. Важной задачей является привлечение внимания специалистов к необходимости безотлагательного начала тромбопрофилактики. Рассмотрены ведущие подходы к выбору антитромботической терапии на основании клинических шкал CHA2DS2-VASC и HAS-BLED, обсуждены выгодные и отрицательные характеристики антагонистов витамина K и новых пероральных антикоагулянтов, а также особенности условий использования отдельных представителей препаратов этих групп.
Литература
1. Palamaner S. S. G., Bhave P., Girotra S. et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circulation: Cardiovascular Quality and Outcomes. 2017; 10: e003418. doi: 10.1161/CIRCOUTCOMES.116.003418
2. Williams B., Evans M., Honushefsky A., Berger P. Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation. J Am Coll Cardiol. 2017; 69 (11): 549. doi: 10.1161/JAHA.117.006669
3. Frost J., Campos-Outcalt D., Hoelting D. et al. Atrial fibrillation guideline summary. The Annals of Family Medicine. 2017;15(5):490-491. doi: 10.1370/afm.2146.
4. Galvão Braga C., Ramos V., Vieira C. et al. New-onset atrial fibrillation during acute coronary syndromes: Predictors and prognosis. Revista Portuguesa de Cardiologia. 2014; 33 (5): 281-287. doi: 10.1016/j.repc.2013.10.017
5. Willey V., Franchino-Elder J., Fu A. et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open. 2018; 8 (6): e020676. doi: 10.1136/bmjopen-2017-020676
6. Khurshid S., Weng L., Hulme O., Ellinor P., Lubitz S. Factors associated with anticoagulation delay following new-onset atrial fibrillation. Am J Cardiol. 2017; 120 (8): 1316-1321. doi: 10.1016/j.amjcard.2017.07.017
7. Haim M., Hoshen M., Reges O. et al. Prospective National Study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-tvalvular atrial fibrillation. J Am Heart Assoc. 2015; 4: e001486. doi: 10.1161/JAHA.114.001486
8. Camm A., Accetta G., Ambrosio G. et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2016; 103 (4): 307-314. doi: 10.1136/heartjnl-2016-309832
9. Lip G., Nieuwlaat R., Pisters R., Lane D., Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010; 137 (2): 263-272. doi: 10.1378/chest.09-1584
10. Pisters R., Lane D., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138 (5): 1093-1100. doi: 10.1378/chest.10-0134
11. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962. doi: 10.1093/ejcts/ezw313
12. Zirlik A., Bode C. Vitamin K antagonists: relative strengths and weaknesses vs direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2016; 43 (3): 365-379. doi: 10.1007/s11239-016-1446-0
13. Ageno W., Gallus A., Wittkowsky A. et al. Oral anticoagulant therapy. Chest. 2012; 141 (2): e44S-e88S. doi: 10.1378/chest.11-2292
14. Voukalis C., Lip G., Shantsila E. Emerging tools for stroke prevention in atrial fibrillation. EBioMedicine. 2016; 4: 26-39. doi: 10.1016/j.ebiom.2016.01.017
15. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17 (10): 1467-1507. doi: 10.1093/europace/euv309
16. Patel M., Mahaffey K., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011; 365 (10): 883-891. doi: 10.1056/NEJMoa1009638
17. Connolly S., Ezekowitz M., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361 (12): 1139-1151. doi: 10.1056/NEJMoa0905561
18. Bassand J., Accetta G., Camm A. et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37 (38): 2882-2889. doi: 10.1093/eurheartj/ehw233
2. Williams B., Evans M., Honushefsky A., Berger P. Clinical prediction model for time in therapeutic range while on warfarin in newly diagnosed atrial fibrillation. J Am Coll Cardiol. 2017; 69 (11): 549. doi: 10.1161/JAHA.117.006669
3. Frost J., Campos-Outcalt D., Hoelting D. et al. Atrial fibrillation guideline summary. The Annals of Family Medicine. 2017;15(5):490-491. doi: 10.1370/afm.2146.
4. Galvão Braga C., Ramos V., Vieira C. et al. New-onset atrial fibrillation during acute coronary syndromes: Predictors and prognosis. Revista Portuguesa de Cardiologia. 2014; 33 (5): 281-287. doi: 10.1016/j.repc.2013.10.017
5. Willey V., Franchino-Elder J., Fu A. et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open. 2018; 8 (6): e020676. doi: 10.1136/bmjopen-2017-020676
6. Khurshid S., Weng L., Hulme O., Ellinor P., Lubitz S. Factors associated with anticoagulation delay following new-onset atrial fibrillation. Am J Cardiol. 2017; 120 (8): 1316-1321. doi: 10.1016/j.amjcard.2017.07.017
7. Haim M., Hoshen M., Reges O. et al. Prospective National Study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-tvalvular atrial fibrillation. J Am Heart Assoc. 2015; 4: e001486. doi: 10.1161/JAHA.114.001486
8. Camm A., Accetta G., Ambrosio G. et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2016; 103 (4): 307-314. doi: 10.1136/heartjnl-2016-309832
9. Lip G., Nieuwlaat R., Pisters R., Lane D., Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest. 2010; 137 (2): 263-272. doi: 10.1378/chest.09-1584
10. Pisters R., Lane D., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138 (5): 1093-1100. doi: 10.1378/chest.10-0134
11. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37 (38): 2893-2962. doi: 10.1093/ejcts/ezw313
12. Zirlik A., Bode C. Vitamin K antagonists: relative strengths and weaknesses vs direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2016; 43 (3): 365-379. doi: 10.1007/s11239-016-1446-0
13. Ageno W., Gallus A., Wittkowsky A. et al. Oral anticoagulant therapy. Chest. 2012; 141 (2): e44S-e88S. doi: 10.1378/chest.11-2292
14. Voukalis C., Lip G., Shantsila E. Emerging tools for stroke prevention in atrial fibrillation. EBioMedicine. 2016; 4: 26-39. doi: 10.1016/j.ebiom.2016.01.017
15. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17 (10): 1467-1507. doi: 10.1093/europace/euv309
16. Patel M., Mahaffey K., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011; 365 (10): 883-891. doi: 10.1056/NEJMoa1009638
17. Connolly S., Ezekowitz M., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361 (12): 1139-1151. doi: 10.1056/NEJMoa0905561
18. Bassand J., Accetta G., Camm A. et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37 (38): 2882-2889. doi: 10.1093/eurheartj/ehw233
Опубликована
2019-10-01
Как цитировать
БАГРИЙ, А. Э. et al.
АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ ПРИ ВПЕРВЫЕ ВЫЯВЛЕННОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ.
Университетская клиника, [S.l.], n. 3(32), p. 54-59, окт. 2019.
ISSN 1819-0464. Доступно на: <http://journal.dnmu.ru/index.php/UC/article/view/338>. Дата доступа: 22 ноя. 2024
doi: https://doi.org/10.26435/uc.v0i3(32).338.
Раздел
Обзоры
